SAN DIEGO, April 8, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 ...
SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities ...
LOS ANGELES, April 16, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ImmunityBio, Inc., (“Super Micro” or the "Company") (NASDAQ: IBRX) investors of a class action on behalf of investors that ...
NEW YORK, April 15, 2026 /PRNewswire/ -- IMPORTANT DATE: May 26, 2026. Investors who wish to seek appointment as lead plaintiff in the ImmunityBio, Inc. (NASDAQ: IBRX) securities class action must ...
There is no cost or obligation to speak with an attorney. IMMUNITYBIO, INC. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY: The complaint alleges that, throughout the Class Period, Defendants ...
NEW YORK, March 29, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ImmunityBio, Inc. ("ImmunityBio" or the "Company") ...
IMMUNITYBIO, INC. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY: The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results